Frontline Forum | Beyond Steroids: Topical Dermatological Efficacy and Patient-Centric Perspectives

Lisa Swanson, MD, FAAD, sheds light on the enhanced accessibility of ruxolitinib cream, highlighting its improved availability for patients in need.

Brad Glick, DO, MPH, FAAD, notes the absence of location restrictions with topical ruxolitinib cream, distinguishing it from topical corticosteroids. The panel discusses the cyclic pattern of steroid use and the potential of ruxolitinib cream as a continuous treatment option.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.